Soligenix (NASDAQ:SNGX) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Wednesday. They presently have a $2.70 price target on the biopharmaceutical company’s stock, down from their prior price target of $5.50. HC Wainwright’s target price would indicate a potential upside of 25.00% from the company’s previous close.
Separately, Maxim Group set a $5.00 price objective on Soligenix and gave the stock a “buy” rating in a report on Tuesday, October 31st.
Soligenix (SNGX) opened at $2.16 on Wednesday. The company has a market capitalization of $19.21 and a PE ratio of -2.08. Soligenix has a twelve month low of $1.74 and a twelve month high of $5.08.
Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.15. The company had revenue of $1.82 million for the quarter, compared to the consensus estimate of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. analysts forecast that Soligenix will post -1.2 EPS for the current year.
In other news, insider Spa Essetifin acquired 293,510 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were bought at an average cost of $2.12 per share, for a total transaction of $622,241.20. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 5.03% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/02/hc-wainwright-downgrades-soligenix-sngx-to-neutral.html.
Soligenix Company Profile
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.